首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5727篇
  免费   257篇
  国内免费   202篇
耳鼻咽喉   140篇
儿科学   75篇
妇产科学   214篇
基础医学   173篇
口腔科学   91篇
临床医学   373篇
内科学   770篇
皮肤病学   91篇
神经病学   320篇
特种医学   180篇
外科学   1458篇
综合类   705篇
预防医学   222篇
眼科学   57篇
药学   274篇
  1篇
中国医学   99篇
肿瘤学   943篇
  2023年   93篇
  2022年   278篇
  2021年   289篇
  2020年   259篇
  2019年   225篇
  2018年   209篇
  2017年   188篇
  2016年   209篇
  2015年   202篇
  2014年   465篇
  2013年   384篇
  2012年   401篇
  2011年   374篇
  2010年   329篇
  2009年   301篇
  2008年   321篇
  2007年   302篇
  2006年   276篇
  2005年   223篇
  2004年   162篇
  2003年   127篇
  2002年   88篇
  2001年   77篇
  2000年   95篇
  1999年   54篇
  1998年   47篇
  1997年   31篇
  1996年   36篇
  1995年   17篇
  1994年   20篇
  1993年   15篇
  1992年   13篇
  1991年   11篇
  1990年   4篇
  1989年   7篇
  1988年   11篇
  1987年   5篇
  1986年   4篇
  1985年   9篇
  1984年   2篇
  1983年   3篇
  1982年   7篇
  1981年   2篇
  1980年   1篇
  1979年   2篇
  1977年   3篇
  1976年   1篇
  1975年   1篇
  1974年   2篇
  1971年   1篇
排序方式: 共有6186条查询结果,搜索用时 15 毫秒
1.
《Pancreatology》2022,22(5):598-607
BackgroundResections for intraductal papillary mucinous neoplasia (IPMN) have increased dramatically during the last decade. Recurrence pattern and impact of adjuvant chemotherapy for solid pancreatic ductal adenocarcinoma (PDAC) is well known, but not for invasive IPMN (inv-IPMN).ObjectivesTo elucidate the impact of spatio-temporal recurrence pattern and adjuvant chemotherapy on overall survival for inv-IPMN compared with PDAC.MethodsWe conducted a retrospective single-center observational study of consecutive patients ≥18 years of age who underwent resection for inv-IPMN or PDAC at Karolinska University Hospital, between 2009 and 2018. Different initial recurrence sites and time frames as well as predictors for death were assessed with multivariable Cox and logistic regressions. Survival analyses were performed using the Kaplan-Meier model and log rank test.ResultsOf 396 resected patients, 92 were inv-IPMN and 304 PDAC. Both recurrence rate and death rate within three-years were lower for inv-IPMN compared to PDAC (p = 0.006 and p = 0.007 respectively). Across the whole cohort, the most common recurrence patterns were multi-site (25%), single-site liver (21%) and single-site locoregional (10%) recurrence. The most prominent predictors for death in multivariable Cox regression, especially if occurred within the first year, were multi-site (HR 17.0), single-site peritoneal (HR 13.6) and single-site liver (HR 13.1) recurrence. These predictors were less common in inv-IPMN compared to PDAC (p = 0.007). The effect of adjuvant chemotherapy was similar in the two groups.ConclusionResected inv-IPMN exhibits a less aggressive recurrence pattern than PDAC that translates into a more favorable overall survival.  相似文献   
2.
3.
4.
目的探讨血清上皮型钙黏蛋白(E-Cad)、胃泌素-17(G-17)水平和肿瘤组织中人类表皮生长因子受体2(HER-2)表达与胃癌患者术后复发风险的相关性。方法选取行胃癌根治术治疗的胃癌患者92例,检测术前血清E-Cad、G-17水平和肿瘤组织HER-2的表达。对所有患者随访5年,以胃癌复发或随访满5年为随访终点。以胃良性病变患者92例作为对照组。收集所有胃癌患者的临床资料(性别、年龄、临床分期、分化程度、复发情况等)。采用受试者工作特征(ROC)曲线评估各项指标判断胃癌复发的效能。采用Cox回归分析评估影响胃癌患者复发的危险因素。采用Kaplan-Meier生存曲线评估胃癌患者的5年复发情况。结果胃癌组血清G-17水平和肿瘤组织HER-2阳性率均显著高于对照组(P=0.000),血清E-Cad水平显著低于对照组(P=0.000)。血清E-Cad、G-17水平及肿瘤组织HER-2阳性率与胃癌的TNM分期、分化情况及是否复发有关(P<0.05),与性别无关(P>0.05)。ROC曲线分析结果显示,E-Cad、G-17、HER-2单项检测与联合检测判断胃癌复发的曲线下面积(AUC)分别为0.775、0.822、0.603、0.950。Kaplan-Meier生存曲线分析结果显示,胃癌复发患者E-Cad低表达组复发率高于高表达组(P<0.05),而G-17低表达组、HER-2低表达组复发率低于G-17高表达组、HER-2高表达组(P<0.05)。Cox回归分析结果显示,E-Cad水平降低、G-17水平升高、HER-2表达升高均是胃癌复发的危险因素[风险比(HR)分别为0.835、1.568、3.981,95%可信区间(CI)分别为0.767~0.909、1.292~1.904、1.504~10.538]。结论E-Cad、G-17、HER-2在预测胃癌患者根治术后复发中均有重要价值。  相似文献   
5.
《Cirugía espa?ola》2022,100(11):709-717
ObjectiveMost evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma.MethodMulticentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS).ResultsA total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P=0.001), with smaller tumoral size (P=0.044) and reported higher rates of substance abuse.including tobacco use (P=0.034) and parenteral drug consumption (P=0.001). No differences were found in administered therapies (P=301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P=0.756) and DFS (65 vs. 68%; P=0.338) were observed.ConclusionThe present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients.  相似文献   
6.
7.
目的 探讨胆囊结石合并胆总管结石(CBDS)术后患者复发情况及危险因素。方法 纳入114例2019年1月~2020年12月在本院行ECRP联合LC治疗的胆囊结石合并CBDS患者,回顾性分析其临床资料,根据所选患者ECRP联合LC术后随访1年内是否复发(REC)将其分为REC组(32例)和未REC组(82例)。回顾性统计胆囊结石合并CBDS术后患者REC情况,比较REC组和未REC组的临床资料,并分析胆囊结石合并CBDS术后患者REC的危险因素。结果 114例胆囊结石合并CBDS术后患者REC32例,发生率28.07%。胆囊结石合并CBDS术后患者REC的危险因素为胆道感染、胆道口括约肌切开、术者经验≤3年、胆道括约肌功能障碍(OR=4.170、4.047、3.568、3.367,P<0.05)。结论 胆囊结石合并CBDS术后患者REC的危险因素与胆道感染、胆道口括约肌切开、术者经验≤3年、胆道括约肌功能障碍密切相关,可据此针对性制定临床治疗及护理干预措施方案,以降低胆囊结石合并CBDS术后患者REC率。  相似文献   
8.
《Pancreatology》2022,22(6):782-788
BackgroundThe different oncological outcomes of invasive intraductal papillary mucinous neoplasm (I-IPMN) and pancreatic ductal adenocarcinoma (PDAC) are debated. This study aimed to compare disease recurrence patterns and histopathological characteristics in patients with resected I-IPMN and PDAC.MethodsConsecutive patients undergoing surgical resection for stage I-III I-IPMN or PDAC between 2010 and 2016 were retrospectively analyzed. Patients treated with neoadjuvant therapy or resected for Tis neoplasia were excluded. All surgical specimens were re-staged according to AJCC-8th-edition.ResultsA total of 330 patients were included, of whom 43 had I-IPMN and 287 had PDAC. Median follow-up time was 26.7 (1.3–92.3) months and estimated median disease-free survival (DFS) was 60.3 months (47.2–73.4) for I-IPMN and 23.8 (19.3–28.2) months for PDAC (p < 0.001). During follow-up, 32.6% of I-IPMN and 67.9% of PDAC patients experienced recurrence (p < 0.001). The sites of first recurrence were the lungs (38.5% vs 13.1%, p = 0.027), liver (28.6% vs 45.0%, p = 0.180) and local (15.4% vs 36.6%, p = 0.101) for I-IPMN and PDAC, respectively. At multivariate analysis, I-IPMN histology remained an independent predictive factor for longer DFS (OR 0.528, CI 95% 0.278–1.000, p = 0.050), regardless of stage or adjuvant chemotherapy. I-IPMN and PDAC differed in rates of neuroinvasion (51.2% vs 97.2%) and positive lymph node status (N+) (46.5% vs 82.7%), especially in patients with lower T status.ConclusionI-IPMN showed a different recurrence pattern compared to PDAC, with a higher lung tropism, and longer DFS. This different biological behavior is associated with lower rates of neuroinvasion and nodal involvement, especially in early-stage disease.  相似文献   
9.
Diffuse cutaneous leishmaniasis is a rare universal disease associated with an inadequate host cell immune response, caused by different species: infantum, aethiopica, major, mexicana, and others, which presents the challenge of a poor therapeutic response. In Brazil, it is caused by L. amazonensis. A case confirmed by histopathology with an abundance of vacuolated macrophages full of amastigotes and lymphocyte scarcity, identified by RFLP-ITS1PCR and in vitro decrease and exhaustion of the host cell immune response to L. amazonensis antigen, was treated early (3 months after the onset) with Glucantime (2 months) and allopurinol (29 months) with clinical cure, after a follow-up for 30 months after treatment.  相似文献   
10.
目的:探讨以伊沙佐米为基础的化疗方案治疗复发难治多发性骨髓瘤(RRMM)的临床效果及相关不良反应。方法:收集2018年10月至2020年2月山东省菏泽市立医院、邹城市人民医院接受≥2个疗程以伊沙佐米为基础化疗方案治疗的RRMM患者21例,其中既往接受过含硼替佐米方案治疗患者15例,接受过含来那度胺方案治疗患者10例,接受过含以上两种药物方案治疗患者6例。采用伊沙佐米(4 mg,口服,第1、8、15天)联合其他药物(地塞米松、环磷酰胺或来那度胺)的两药或三药方案治疗。治疗第2、4个周期后评估其治疗效果及安全性。结果:21例RRMM患者治疗2个周期后评估总反应率(ORR)为38.09%(8/21),其中部分缓解(PR)6例、非常好的部分缓解(VGPR)2例;4个周期后ORR为57.14%(12/21),其中PR 7例、VGPR 4例、完全缓解(CR)1例。以伊沙佐米为基础的化疗方案3~4级不良反应发生率为23.81%(5/21),血液学不良反应包括中性粒细胞减少、血小板降低及贫血,其他常见不良反应包括消化道反应、乏力、低钾血症等,周围神经不良反应均为2级及以下。结论:以伊沙佐米为基础的化疗方案对RRMM治疗有效,安全性较好。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号